ACXP Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (21 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	301 340
Vidutinė apimtis	75 472.00
Rinkos kapitalizacija	44.20M
EPS	$-282.95 ( 2024-05-15 )
Kita pelno data	( $-0.280 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.36
ATR14	$0.0370 (1.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-23	Luci David P	Buy	250 000	Stock Option
2024-02-23	Shawah Robert G.	Buy	145 000	Stock Option
2024-02-23	Deluccia Robert J	Buy	250 000	Stock Option
2024-01-19	Sailer Carl	Buy	19 737	Common Stock
2024-01-19	Sailer Carl	Sell	19 737	Warrants for Common Stock

INSIDER POWER
76.59
Last 61 transactions
Buy: 3 435 791 \| Sell: 229 212

Tūris Koreliacija

Ilgas: -0.13 (neutral)

Trumpas: -0.07 (neutral)

Signal:(64.884) Neutral

Acurx Pharmaceuticals, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
BNRG	0.947
QNRX	0.945
RMCF	0.944
AGFY	0.94
ACAD	0.94
FLGT	0.939
FWRD	0.938
SINT	0.937
AMPH	0.935
GOVX	0.931

10 Labiausiai neigiamai susiję koreliacijos
KINS	-0.953
GHRS	-0.943
TAYD	-0.932
ESTA	-0.931
CHW	-0.928
MMYT	-0.928
AMZN	-0.928
CRBP	-0.926
ALLT	-0.924
ROAD	-0.923

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Acurx Pharmaceuticals, Koreliacija - Valiuta/Žaliavos

-0.28
( neutral )

-0.17
( neutral )

0.00
( neutral )

0.16
( neutral )

0.52
( weak )

-0.34
( neutral )

Acurx Pharmaceuticals, Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-1.150

FY	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-1.150

FY	2022
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$-1.120

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.490

Financial Reports:

No articles found.

Acurx Pharmaceuticals, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Acurx Pharmaceuticals,

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.